Diabetic Nephropathy

Dulaglutide Reduces CV Events, Renal Progression in Type 2 Diabetes

Publish Date June 11, 2019

In the REWIND trial of type 2 diabetes patients, dulaglutide modestly reduced cardiovascular events and progression of kidney disease for at least 5 years.

Ertugliflozin Linked to Better Renal Function in Type 2 Diabetes

Publish Date June 11, 2019 6:30 am

Ertugliflozin may be protective of renal function in patients with type 2 diabetes.

Young Age at Type 1 Diabetes Onset Predicts Higher Kidney Disease Risk

Publish Date June 11, 2019

Type 1 diabetes onset before the age of 14 years is independently associated with a greater risk of kidney disease compared with later age at onset, according to a new study.

Dapagliflozin Shown to Slow Diabetic Kidney Disease Progression

Publish Date June 10, 2019

Protective effect is driven largely by a sustained 40% decrease in estimate glomerular filtration rate to below 60 mL/min/1.73 m2.

ADA Updates Diabetic Nephropathy Recommendations

Publish Date June 6, 2019

Per the ADA update, clinicians should consider prescribing a SGLT2 inhibitor in type 2 diabetes patients with diabetic nephropathy.

Nearly Half of Type 2 Diabetics Have Undiagnosed CKD

Publish Date May 13, 2019

Undiagnosed chronic kidney disease is present in 49% of patients with type 2 diabetes mellitus in the United States, a study found.

Atrasentan Tied to Lower Risk for Kidney Events in T2DM With CKD

Publish Date April 19, 2019

Reduced risk seen for primary composite renal end point event; more frequent fluid retention, anemia reported

Nondihydropyridine CCBs May Be an Effective Treatment Option for Proteinuria in Certain Patients

Publish Date April 22, 2019

Nondihydropyridine calcium channel blockers (non-DHP CCBs) appear to reduce proteinuria in patients with diabetic kidney disease

Canagliflozin Lowers ESRD Risk in Diabetic Kidney Disease

Publish Date April 15, 2019

In a study of patients with type 2 diabetes and chronic kidney disease, canagliflozin, an SGLT2 inhibitor, decreased the risk of end-stage renal disease by 32% compared with placebo.

Invokana sNDA Seeking Treatment of Chronic Kidney Disease in T2D Patients

Publish Date April 1, 2019

Janssen announced the submission of a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for Invokana (canagliflozin) to reduce the risk of end-stage renal disease and renal or cardiovascular (CV) death in adults with type 2 diabetes and chronic kidney disease.